
Amy Petrin
Dr. Julie Petrin — Director, Strategy and Impact at MS Canada, a person living with MS and researcher on healthcare access for Canadians with MS.
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
Sep 2, 2026
Moving Science: The impact of Neurofilament light on MS Care
2:09
2:20
2:36
2:59
11:04

Simon ThebaultHOST
So I think the first question, I think a very simple question for all three of us might be, what does neurofilament light chain represent for you? Julie, perhaps we could start with you.

Amy PetrinGUEST
So just to give a bit of context, I'm going to be speaking primarily today from my perspective as someone with lived experience, diagnosed when I was 16 years old.

Amy PetrinGUEST
Just to give a bit of context to anyone listening, And I think why it's important and why we're all here today and why I was happy to join the call today was essentially because you don't get much access to being able to know what's going on in your body.

Amy PetrinGUEST
Essentially, when you're diagnosed with MS, you're diagnosed with a disease that's very unpredictable.
8 MINS LATER

Simon ThebaultHOST
Julie, how about from your perspective, is the attraction to a blood-based biomarker different to what Ron's mentioning there?